Centralized Pan-Asian Survey on the Under Treatment of Hypercholesterolemia
Sponsor: AstraZeneca
This observational or N/A phase trial investigates Hypercholesterolemia and is currently completed. AstraZeneca leads this study, which shows 8 recorded versions since 2008 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
8 versions recorded-
Dec 2025 — Present [monthly]
Completed
-
Sep 2025 — Dec 2025 [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed
-
Apr 2018 — Jun 2018 [monthly]
Completed
Phase: NA → None
-
Jan 2017 — Apr 2018 [monthly]
Completed NA
First recorded
May 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Ampang, Malaysia , Baguio City, Philippines , Bandung, Indonesia , Bangkoknoi, Thailand , Bangsar, Malaysia , Batu Caves, Malaysia , Bucheon-si, South Korea , Bundang, South Korea , Busan, South Korea , Cheonan, South Korea and 49 more locations